GeneDx (NASDAQ:WGS) Downgraded to Strong Sell Rating by Zacks Research

Zacks Research downgraded shares of GeneDx (NASDAQ:WGS) from a hold rating to a strong sell rating in a research report report published on Monday,Zacks.com reports.

WGS has been the subject of several other reports. Craig Hallum restated a “buy” rating and set a $85.00 target price on shares of GeneDx in a research note on Tuesday, May 5th. Wells Fargo & Company reiterated an “overweight” rating and issued a $75.00 price target (down from $155.00) on shares of GeneDx in a research note on Tuesday, May 5th. Canaccord Genuity Group set a $75.00 price target on GeneDx and gave the stock a “buy” rating in a report on Tuesday, May 5th. Weiss Ratings downgraded GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. Finally, BTIG Research decreased their target price on GeneDx from $170.00 to $90.00 and set a “buy” rating on the stock in a research report on Tuesday, May 5th. Six analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $87.43.

GeneDx Stock Performance

NASDAQ:WGS opened at $68.65 on Monday. The stock has a 50 day simple moving average of $54.39 and a 200 day simple moving average of $81.24. The stock has a market cap of $2.04 billion, a P/E ratio of -25.62 and a beta of 1.96. GeneDx has a 1-year low of $32.21 and a 1-year high of $170.87. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.22). GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.The firm had revenue of $102.25 million for the quarter, compared to the consensus estimate of $112.46 million. During the same quarter in the previous year, the business earned ($0.23) EPS. Research analysts anticipate that GeneDx will post -1 earnings per share for the current year.

Insider Transactions at GeneDx

In other GeneDx news, Director Casdin Capital, Llc acquired 185,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The stock was acquired at an average price of $42.60 per share, for a total transaction of $7,881,000.00. Following the acquisition, the director directly owned 3,367,164 shares in the company, valued at $143,441,186.40. This represents a 5.81% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Keith A. Meister bought 533,758 shares of GeneDx stock in a transaction on Thursday, May 7th. The shares were acquired at an average cost of $37.86 per share, for a total transaction of $20,208,077.88. Following the completion of the acquisition, the director directly owned 3,761,908 shares in the company, valued at approximately $142,425,836.88. The trade was a 16.53% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders acquired 2,256,420 shares of company stock valued at $93,144,340 and sold 21,699 shares valued at $1,295,646. 25.17% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On GeneDx

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Kestra Advisory Services LLC acquired a new position in shares of GeneDx in the 4th quarter worth approximately $27,000. Fifth Third Bancorp bought a new position in GeneDx during the first quarter worth $31,000. Quarry LP lifted its holdings in GeneDx by 248.8% in the third quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after buying an additional 209 shares during the period. Ramirez Asset Management Inc. acquired a new stake in GeneDx during the 4th quarter worth about $33,000. Finally, Greenline Wealth Management LLC bought a new stake in shares of GeneDx during the 4th quarter valued at about $33,000. 61.72% of the stock is owned by institutional investors and hedge funds.

GeneDx News Roundup

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: No clearly positive company-specific news was reported in the latest articles.
• Neutral Sentiment: Several law firms, including Rosen, Faruqi & Faruqi, Robbins Geller, Kessler Topaz, and others, reminded investors of the August 3, 2026 deadline to seek lead-plaintiff status in the existing class action lawsuit against GeneDx. Article Title
• Neutral Sentiment: Hagens Berman said it is investigating claims in the securities case, but this largely reiterates the ongoing lawsuit rather than adding new operational developments. Article Title
• Negative Sentiment: Zacks Research downgraded GeneDx from hold to strong sell, reinforcing bearish sentiment around the shares. Article Title
• Negative Sentiment: The repeated class-action announcements may weigh on the stock by highlighting potential legal liability, investor-loss claims, and uncertainty around prior disclosure practices. Article Title

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.